Hereditary breast cancer; Genetic penetrance and current status with BRCA
The most important cause of developing hereditary breast cancer is germline mutations occurring in breast cancer (BCs) susceptibility genes, for example, BRCA1, BRCA2, TP53, CHEK2, PTEN, ATM, and PPM1D. Many BC susceptibility genes can be grouped into two classes, high‐ and low‐penetrance genes, eac...
Saved in:
Published in | Journal of cellular physiology Vol. 234; no. 5; pp. 5741 - 5750 |
---|---|
Main Authors | , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Wiley Subscription Services, Inc
01.05.2019
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | The most important cause of developing hereditary breast cancer is germline mutations occurring in breast cancer (BCs) susceptibility genes, for example, BRCA1, BRCA2, TP53, CHEK2, PTEN, ATM, and PPM1D. Many BC susceptibility genes can be grouped into two classes, high‐ and low‐penetrance genes, each of which interact with multiple genes and environmental factors. However, the penetrance of genes can also be represented by a spectrum, which ranges between high and low. Two of the most common susceptibility genes are BRCA1 and BRCA2, which perform vital cellular functions for repair of homologous DNA. Loss of heterozygosity accompanied by hereditary mutations in BRCA1 or BRCA2 increases chromosomal instability and the likelihood of cancer, as well as playing a key role in stimulating malignant transformation. With regard to pathological features, familial breast cancers caused by BRCA1 mutations usually differ from those caused by BRCA2 mutations and nonfamilial BCs. It is essential to acquire an understanding of these pathological features along with the genetic history of the patient to offer an individualized treatment. Germline mutations in BRCA1 and BRCA2 genes are the main genetic and inherited factors for breast and ovarian cancer. In fact, these mutations are very important in developing early onset and increasing the risk of familial breast and ovarian cancer and responsible for 90% of hereditary BC cases. Therefore, according to the conducted studies, screening of BRCA1 and BRCA2 genes is recommended as an important marker for early detection of all patients with breast or ovarian cancer risk with family history of the disease. In this review, we summarize the role of hereditary genes, mainly BRCA1 and BRCA2, in BC. |
---|---|
AbstractList | The most important cause of developing hereditary breast cancer is germline mutations occurring in breast cancer (BCs) susceptibility genes, for example, BRCA1, BRCA2, TP53, CHEK2, PTEN, ATM, and PPM1D. Many BC susceptibility genes can be grouped into two classes, high- and low-penetrance genes, each of which interact with multiple genes and environmental factors. However, the penetrance of genes can also be represented by a spectrum, which ranges between high and low. Two of the most common susceptibility genes are BRCA1 and BRCA2, which perform vital cellular functions for repair of homologous DNA. Loss of heterozygosity accompanied by hereditary mutations in BRCA1 or BRCA2 increases chromosomal instability and the likelihood of cancer, as well as playing a key role in stimulating malignant transformation. With regard to pathological features, familial breast cancers caused by BRCA1 mutations usually differ from those caused by BRCA2 mutations and nonfamilial BCs. It is essential to acquire an understanding of these pathological features along with the genetic history of the patient to offer an individualized treatment. Germline mutations in BRCA1 and BRCA2 genes are the main genetic and inherited factors for breast and ovarian cancer. In fact, these mutations are very important in developing early onset and increasing the risk of familial breast and ovarian cancer and responsible for 90% of hereditary BC cases. Therefore, according to the conducted studies, screening of BRCA1 and BRCA2 genes is recommended as an important marker for early detection of all patients with breast or ovarian cancer risk with family history of the disease. In this review, we summarize the role of hereditary genes, mainly BRCA1 and BRCA2, in BC. The most important cause of developing hereditary breast cancer is germline mutations occurring in breast cancer (BCs) susceptibility genes, for example, BRCA1, BRCA2, TP53, CHEK2, PTEN, ATM, and PPM1D. Many BC susceptibility genes can be grouped into two classes, high- and low-penetrance genes, each of which interact with multiple genes and environmental factors. However, the penetrance of genes can also be represented by a spectrum, which ranges between high and low. Two of the most common susceptibility genes are BRCA1 and BRCA2, which perform vital cellular functions for repair of homologous DNA. Loss of heterozygosity accompanied by hereditary mutations in BRCA1 or BRCA2 increases chromosomal instability and the likelihood of cancer, as well as playing a key role in stimulating malignant transformation. With regard to pathological features, familial breast cancers caused by BRCA1 mutations usually differ from those caused by BRCA2 mutations and nonfamilial BCs. It is essential to acquire an understanding of these pathological features along with the genetic history of the patient to offer an individualized treatment. Germline mutations in BRCA1 and BRCA2 genes are the main genetic and inherited factors for breast and ovarian cancer. In fact, these mutations are very important in developing early onset and increasing the risk of familial breast and ovarian cancer and responsible for 90% of hereditary BC cases. Therefore, according to the conducted studies, screening of BRCA1 and BRCA2 genes is recommended as an important marker for early detection of all patients with breast or ovarian cancer risk with family history of the disease. In this review, we summarize the role of hereditary genes, mainly BRCA1 and BRCA2, in BC.The most important cause of developing hereditary breast cancer is germline mutations occurring in breast cancer (BCs) susceptibility genes, for example, BRCA1, BRCA2, TP53, CHEK2, PTEN, ATM, and PPM1D. Many BC susceptibility genes can be grouped into two classes, high- and low-penetrance genes, each of which interact with multiple genes and environmental factors. However, the penetrance of genes can also be represented by a spectrum, which ranges between high and low. Two of the most common susceptibility genes are BRCA1 and BRCA2, which perform vital cellular functions for repair of homologous DNA. Loss of heterozygosity accompanied by hereditary mutations in BRCA1 or BRCA2 increases chromosomal instability and the likelihood of cancer, as well as playing a key role in stimulating malignant transformation. With regard to pathological features, familial breast cancers caused by BRCA1 mutations usually differ from those caused by BRCA2 mutations and nonfamilial BCs. It is essential to acquire an understanding of these pathological features along with the genetic history of the patient to offer an individualized treatment. Germline mutations in BRCA1 and BRCA2 genes are the main genetic and inherited factors for breast and ovarian cancer. In fact, these mutations are very important in developing early onset and increasing the risk of familial breast and ovarian cancer and responsible for 90% of hereditary BC cases. Therefore, according to the conducted studies, screening of BRCA1 and BRCA2 genes is recommended as an important marker for early detection of all patients with breast or ovarian cancer risk with family history of the disease. In this review, we summarize the role of hereditary genes, mainly BRCA1 and BRCA2, in BC. |
Author | Sandry, Ryan Lam, Alfred King‐yin Mahdavi, Morteza Gopalan, Vinod Pillai, Suja Nassiri, Mohammadreza Kooshyar, Mohammad Mahdi Vakili‐Azghandi, Masoume Avan, Amir |
Author_xml | – sequence: 1 givenname: Morteza surname: Mahdavi fullname: Mahdavi, Morteza organization: Institute of Biotechnology, Ferdowsi University of Mashhad – sequence: 2 givenname: Mohammadreza orcidid: 0000-0001-7119-8155 surname: Nassiri fullname: Nassiri, Mohammadreza email: nassiryr@um.ac.ir organization: Institute of Biotechnology, Ferdowsi University of Mashhad – sequence: 3 givenname: Mohammad Mahdi surname: Kooshyar fullname: Kooshyar, Mohammad Mahdi organization: Mashhad University of Medical Sciences – sequence: 4 givenname: Masoume orcidid: 0000-0003-1169-9147 surname: Vakili‐Azghandi fullname: Vakili‐Azghandi, Masoume organization: Institute of Biotechnology, Ferdowsi University of Mashhad – sequence: 5 givenname: Amir orcidid: 0000-0002-4968-0962 surname: Avan fullname: Avan, Amir organization: School of Medicine, Griffith University – sequence: 6 givenname: Ryan surname: Sandry fullname: Sandry, Ryan organization: Faculty of Medicine, Mashhad University of Medical Sciences – sequence: 7 givenname: Suja surname: Pillai fullname: Pillai, Suja organization: School of Biomedical Sciences, Faculty of Medicine, The University of Queensland – sequence: 8 givenname: Alfred King‐yin orcidid: 0000-0003-2771-564X surname: Lam fullname: Lam, Alfred King‐yin organization: School of Medicine, Griffith University – sequence: 9 givenname: Vinod orcidid: 0000-0003-0366-9482 surname: Gopalan fullname: Gopalan, Vinod organization: Faculty of Medicine, Mashhad University of Medical Sciences |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/30552672$$D View this record in MEDLINE/PubMed |
BookMark | eNp90UFLwzAUB_Agis7pwS8gAS966JY0TdLiaQ51iqCInkuavGJHl84kZezbmzn1IOjpwcvvPcL_HaJd21lA6ISSESUkHc_1cpTKTGQ7aEBJIZNM8HQXDeIbTQqe0QN06P2cEFIUjO2jA0Y4T4VMB-huBg5ME5Rb48qB8gFrZTW4S3wLFkKj8XJT3aaJlTVY986BDdgHFXqPV014w1fP08kR2qtV6-H4qw7R6831y3SWPDze3k0nD4lmnGUJ5bmpDSdAjMlpIY2QJBW8rhgwKVkms0oTyZlQTEeU6ywX1NSMSZVDTSs2ROfbvUvXvffgQ7lovIa2VRa63pcp5VIIkTMR6dkvOu96Z-PvohJFKnJJZFSnX6qvFmDKpWsWMY7yO6QILrZAu857B_UPoaTcHKCMByg_DxDt-JfVMdzQdDZG2LT_TayaFtZ_ry7vp0_biQ_xWZQJ |
CitedBy_id | crossref_primary_10_1016_j_clbc_2024_01_001 crossref_primary_10_1016_j_isci_2023_108333 crossref_primary_10_1016_j_prp_2024_155318 crossref_primary_10_56050_01205498_2315 crossref_primary_10_3390_women1010002 crossref_primary_10_1113_JP284421 crossref_primary_10_1007_s00432_023_04663_9 crossref_primary_10_1186_s40659_024_00579_x crossref_primary_10_1002_mgg3_1359 crossref_primary_10_1007_s11051_024_06153_6 crossref_primary_10_1097_MS9_0000000000002293 crossref_primary_10_3390_ijms252312585 crossref_primary_10_1016_j_bios_2021_113767 crossref_primary_10_3389_fcell_2020_00160 crossref_primary_10_18097_PBMCR1495 crossref_primary_10_1016_j_jaccao_2019_09_008 crossref_primary_10_1111_ahg_12592 crossref_primary_10_18632_aging_202315 crossref_primary_10_1016_j_biopha_2020_109956 crossref_primary_10_1051_e3sconf_202130802022 crossref_primary_10_1242_dmm_050211 crossref_primary_10_1007_s11033_022_07571_2 crossref_primary_10_1186_s13148_020_00888_4 crossref_primary_10_55489_njcm_130920222120 crossref_primary_10_1002_med_22058 crossref_primary_10_1007_s00268_023_07033_1 crossref_primary_10_1186_s12905_022_01732_y crossref_primary_10_2196_38399 crossref_primary_10_1186_s12935_023_02972_0 crossref_primary_10_3831_KPI_2021_24_1_1 crossref_primary_10_1111_jcmm_14830 crossref_primary_10_1016_j_ijso_2023_100602 crossref_primary_10_3389_fonc_2022_963364 crossref_primary_10_5468_ogs_24054 crossref_primary_10_1186_s12916_022_02489_9 crossref_primary_10_5041_RMMJ_10522 crossref_primary_10_1097_MD_0000000000036905 crossref_primary_10_3343_alm_2020_40_2_114 crossref_primary_10_1016_j_clbc_2022_05_010 crossref_primary_10_1016_j_amjsurg_2024_116005 crossref_primary_10_3389_fonc_2023_1146008 crossref_primary_10_2147_CMAR_S348529 crossref_primary_10_1007_s10549_024_07503_7 crossref_primary_10_12998_wjcc_v9_i12_2923 crossref_primary_10_1186_s12935_025_03663_8 crossref_primary_10_1016_j_ejso_2022_02_019 crossref_primary_10_1016_j_jacr_2023_04_002 crossref_primary_10_3390_life12040524 crossref_primary_10_1111_jcmm_16907 crossref_primary_10_17116_profmed20192203126 crossref_primary_10_1007_s10911_022_09522_w crossref_primary_10_1007_s11033_023_08458_6 crossref_primary_10_1016_j_breast_2023_103602 crossref_primary_10_1038_s41598_021_98737_8 crossref_primary_10_1016_j_ijbiomac_2023_126989 crossref_primary_10_1021_acsmaterialslett_3c00965 crossref_primary_10_1186_s12885_023_10822_5 crossref_primary_10_3390_ijms20122962 crossref_primary_10_1158_1940_6207_CAPR_21_0141 crossref_primary_10_1007_s12687_021_00570_z crossref_primary_10_1038_s41523_022_00443_9 crossref_primary_10_3390_futurepharmacol5010004 crossref_primary_10_3390_cancers13163956 crossref_primary_10_1515_jbcpp_2019_0191 crossref_primary_10_7759_cureus_62160 crossref_primary_10_1177_03000605231223426 crossref_primary_10_1186_s40364_020_00223_2 crossref_primary_10_32635_2176_9745_RBC_2022v68n4_3083 crossref_primary_10_1016_j_tig_2022_11_002 crossref_primary_10_3390_cancers16234022 crossref_primary_10_1002_cam4_70632 crossref_primary_10_1016_j_mrfmmm_2022_111778 crossref_primary_10_3390_ijms25116221 crossref_primary_10_1080_00224499_2022_2144991 crossref_primary_10_1016_j_chphi_2023_100291 crossref_primary_10_1186_s12951_020_00613_6 crossref_primary_10_1016_j_beha_2020_101191 crossref_primary_10_1007_s10549_021_06292_7 crossref_primary_10_1109_TCBB_2020_3027392 crossref_primary_10_1002_jmv_26198 crossref_primary_10_1016_j_jconrel_2022_06_050 crossref_primary_10_1016_j_breast_2021_02_001 crossref_primary_10_3389_fgene_2022_982930 crossref_primary_10_1016_j_hpr_2024_300764 crossref_primary_10_1007_s11033_022_08198_z crossref_primary_10_3892_ije_2021_4 crossref_primary_10_1245_s10434_024_15793_w |
Cites_doi | 10.1016/j.celrep.2014.12.044 10.1186/1471-2407-8-155 10.1186/bcr419 10.1002/(SICI)1098-2264(200002)27:2<130::AID-GCC3>3.0.CO;2-U 10.1007/s12282-012-0432-4 10.1007/s13238-010-0010-5 10.1073/pnas.0800441105 10.7314/APJCP.2013.14.7.4339 10.1038/nature05887 10.1126/science.2270482 10.1001/jama.286.18.2251 10.1200/JCO.2006.09.1066 10.1002/cncr.11310 10.1038/onc.2011.408 10.1158/0008-5472.CAN-03-2970 10.1038/ng1902 10.1186/s12885-015-1934-1 10.1038/87876 10.1126/science.8091231 10.1073/pnas.1706392114 10.1073/pnas.85.9.3044 10.1038/ng1096-185 10.1146/annurev.ge.28.120194.002303 10.1097/PAS.0b013e31826cabbd 10.7326/0003-4819-143-5-200509060-00012 10.1002/ijc.29210 10.1200/JCO.2008.20.5179 10.1007/s11033-011-0958-0 10.1038/onc.2016.502 10.1038/nature03445 10.1371/journal.pgen.1002101 10.1515/BC.2002.030 10.1136/jcp.2005.032151 10.1093/carcin/bgq069 10.1038/82533 10.1158/0008-5472.CAN-08-1569 10.1111/cge.12037 10.1158/0008-5472.CAN-10-1907 10.1002/cncr.24200 10.1200/JCO.2004.05.055 10.1016/j.dnarep.2015.03.002 10.1093/jnci/90.7.484 10.1002/humu.10154 10.1086/375033 10.1038/ng0197-14 10.1086/301903 10.3892/ol.2011.390 10.1056/NEJM198705213162101 10.1007/s10552-007-0118-y 10.1002/humu.20169 10.1016/j.ejmg.2017.07.016 10.1097/01.pas.0000213428.61374.06 10.1016/S0065-2660(08)00601-9 10.1007/s10689-012-9581-z 10.1023/B:JOMG.0000048770.90334.3b 10.1038/sj.bjc.6600008 10.1056/NEJMra0802968 10.1056/NEJMoa031759 |
ContentType | Journal Article |
Copyright | 2018 Wiley Periodicals, Inc. 2019 Wiley Periodicals, Inc. |
Copyright_xml | – notice: 2018 Wiley Periodicals, Inc. – notice: 2019 Wiley Periodicals, Inc. |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7TK 7U7 8FD C1K FR3 K9. P64 RC3 7X8 |
DOI | 10.1002/jcp.27464 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Neurosciences Abstracts Toxicology Abstracts Technology Research Database Environmental Sciences and Pollution Management Engineering Research Database ProQuest Health & Medical Complete (Alumni) Biotechnology and BioEngineering Abstracts Genetics Abstracts MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Genetics Abstracts Technology Research Database Toxicology Abstracts ProQuest Health & Medical Complete (Alumni) Engineering Research Database Neurosciences Abstracts Biotechnology and BioEngineering Abstracts Environmental Sciences and Pollution Management MEDLINE - Academic |
DatabaseTitleList | MEDLINE Genetics Abstracts MEDLINE - Academic CrossRef |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Anatomy & Physiology Biology |
EISSN | 1097-4652 |
EndPage | 5750 |
ExternalDocumentID | 30552672 10_1002_jcp_27464 JCP27464 |
Genre | reviewArticle Journal Article Review |
GroupedDBID | --- -DZ -~X .3N .55 .GA .GJ .Y3 05W 0R~ 10A 1L6 1OB 1OC 1ZS 31~ 33P 36B 3O- 3SF 3WU 4.4 4ZD 50Y 50Z 51W 51X 52M 52N 52O 52P 52S 52T 52U 52W 52X 53G 5GY 5RE 5VS 66C 702 7PT 8-0 8-1 8-3 8-4 8-5 85S 8UM 930 9M8 A03 AAESR AAEVG AAHHS AAHQN AAMNL AANHP AANLZ AAONW AASGY AAXRX AAYCA AAZKR ABCQN ABCUV ABDPE ABEFU ABEML ABIJN ABJNI ABPPZ ABPVW ACAHQ ACBWZ ACCFJ ACCZN ACGFO ACGFS ACNCT ACPOU ACPRK ACRPL ACSCC ACXBN ACXQS ACYXJ ADBBV ADEOM ADIZJ ADKYN ADMGS ADNMO ADOZA ADXAS ADZMN ADZOD AEEZP AEGXH AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFFPM AFGKR AFPWT AFRAH AFWVQ AFZJQ AHBTC AHMBA AIAGR AITYG AIURR AIWBW AJBDE AJXKR ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB ATUGU AUFTA AZBYB AZFZN AZVAB BAFTC BDRZF BFHJK BHBCM BMNLL BMXJE BNHUX BQCPF BROTX BRXPI BY8 CS3 D-E D-F DCZOG DPXWK DR1 DR2 DRFUL DRSTM DU5 EBD EBS EJD EMB EMOBN F00 F01 F04 F5P FEDTE G-S G.N GNP GODZA H.T H.X HBH HF~ HGLYW HHY HHZ HVGLF HZ~ H~9 IH2 IX1 J0M JPC KQQ L7B LATKE LAW LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES M56 MEWTI MK4 MRFUL MRSTM MSFUL MSSTM MVM MXFUL MXSTM N04 N05 N9A NEJ NF~ NNB O66 O9- OHT OIG P2P P2W P2X P4D PALCI PQQKQ Q.N Q11 QB0 QRW R.K RIWAO ROL RWI RWR RX1 RYL S10 SAMSI SUPJJ SV3 TN5 TWZ UB1 UPT V2E V8K VQP W8V W99 WBKPD WH7 WIB WIH WIK WJL WNSPC WOHZO WQJ WRC WXSBR WYB WYISQ X7M XG1 XJT XOL XPP XSW XV2 Y6R YQT YZZ ZGI ZXP ZZTAW ~IA ~WT AAYXX ADXHL AETEA AEYWJ AGHNM AGQPQ AGYGG CITATION CGR CUY CVF ECM EIF NPM PKN 7TK 7U7 8FD AAMMB AEFGJ AGXDD AIDQK AIDYY C1K FR3 K9. P64 RC3 7X8 |
ID | FETCH-LOGICAL-c3534-158dfd50e0dd8197d670265fb3e3773474bc07536a3c0e08c4861df337a8ef1b3 |
IEDL.DBID | DR2 |
ISSN | 0021-9541 1097-4652 |
IngestDate | Fri Jul 11 04:08:28 EDT 2025 Sat Jul 12 04:12:25 EDT 2025 Wed Feb 19 02:31:15 EST 2025 Thu Apr 24 23:06:33 EDT 2025 Tue Jul 01 04:56:52 EDT 2025 Wed Jan 22 17:09:43 EST 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 5 |
Keywords | BRCA breast cancer germline mutations hereditary genes |
Language | English |
License | 2018 Wiley Periodicals, Inc. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c3534-158dfd50e0dd8197d670265fb3e3773474bc07536a3c0e08c4861df337a8ef1b3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Review-3 content type line 23 |
ORCID | 0000-0003-0366-9482 0000-0001-7119-8155 0000-0002-4968-0962 0000-0003-1169-9147 0000-0003-2771-564X |
PMID | 30552672 |
PQID | 2169268707 |
PQPubID | 1006363 |
PageCount | 10 |
ParticipantIDs | proquest_miscellaneous_2157666836 proquest_journals_2169268707 pubmed_primary_30552672 crossref_primary_10_1002_jcp_27464 crossref_citationtrail_10_1002_jcp_27464 wiley_primary_10_1002_jcp_27464_JCP27464 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | May 2019 2019-05-00 20190501 |
PublicationDateYYYYMMDD | 2019-05-01 |
PublicationDate_xml | – month: 05 year: 2019 text: May 2019 |
PublicationDecade | 2010 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States – name: Hoboken |
PublicationTitle | Journal of cellular physiology |
PublicationTitleAlternate | J Cell Physiol |
PublicationYear | 2019 |
Publisher | Wiley Subscription Services, Inc |
Publisher_xml | – name: Wiley Subscription Services, Inc |
References | e_1_2_6_1_53_1 e_1_2_6_1_6_1 e_1_2_6_1_55_1 e_1_2_6_1_8_1 e_1_2_6_1_11_1 e_1_2_6_1_34_1 e_1_2_6_1_2_1 e_1_2_6_1_32_1 e_1_2_6_1_4_1 Phillips K. A. (e_1_2_6_1_51_1) 2000; 18 e_1_2_6_1_27_1 e_1_2_6_1_25_1 e_1_2_6_1_46_1 e_1_2_6_1_29_1 e_1_2_6_1_48_1 e_1_2_6_1_43_1 e_1_2_6_1_45_1 e_1_2_6_1_22_1 e_1_2_6_1_60_1 e_1_2_6_1_20_1 e_1_2_6_1_41_1 e_1_2_6_1_62_1 e_1_2_6_1_15_1 e_1_2_6_1_13_1 e_1_2_6_1_36_1 e_1_2_6_1_57_1 e_1_2_6_1_19_1 e_1_2_6_1_17_1 e_1_2_6_1_59_1 e_1_2_6_1_7_1 e_1_2_6_1_54_1 e_1_2_6_1_9_1 e_1_2_6_1_56_1 e_1_2_6_1_3_1 e_1_2_6_1_12_1 e_1_2_6_1_33_1 e_1_2_6_1_50_1 e_1_2_6_1_5_1 e_1_2_6_1_10_1 e_1_2_6_1_31_1 e_1_2_6_1_52_1 Yoshida K. (e_1_2_6_1_64_1) 2004; 95 Lynch H. T. (e_1_2_6_1_38_1) 1971; 133 e_1_2_6_1_26_1 Murphy C. G. (e_1_2_6_1_42_1) 2010; 24 e_1_2_6_1_24_1 e_1_2_6_1_47_1 e_1_2_6_1_28_1 e_1_2_6_1_49_1 e_1_2_6_1_44_1 e_1_2_6_1_23_1 e_1_2_6_1_61_1 e_1_2_6_1_21_1 e_1_2_6_1_40_1 e_1_2_6_1_63_1 Johannesdottir G. (e_1_2_6_1_30_1) 1996; 56 e_1_2_6_1_16_1 e_1_2_6_1_37_1 e_1_2_6_1_14_1 e_1_2_6_1_35_1 e_1_2_6_1_58_1 e_1_2_6_1_18_1 e_1_2_6_1_39_1 |
References_xml | – ident: e_1_2_6_1_35_1 doi: 10.1016/j.celrep.2014.12.044 – ident: e_1_2_6_1_15_1 doi: 10.1186/1471-2407-8-155 – ident: e_1_2_6_1_5_1 doi: 10.1186/bcr419 – ident: e_1_2_6_1_11_1 doi: 10.1002/(SICI)1098-2264(200002)27:2<130::AID-GCC3>3.0.CO;2-U – ident: e_1_2_6_1_47_1 doi: 10.1007/s12282-012-0432-4 – ident: e_1_2_6_1_63_1 doi: 10.1007/s13238-010-0010-5 – ident: e_1_2_6_1_25_1 doi: 10.1073/pnas.0800441105 – ident: e_1_2_6_1_33_1 doi: 10.7314/APJCP.2013.14.7.4339 – ident: e_1_2_6_1_13_1 doi: 10.1038/nature05887 – ident: e_1_2_6_1_27_1 doi: 10.1126/science.2270482 – ident: e_1_2_6_1_32_1 doi: 10.1001/jama.286.18.2251 – ident: e_1_2_6_1_10_1 doi: 10.1200/JCO.2006.09.1066 – ident: e_1_2_6_1_8_1 doi: 10.1002/cncr.11310 – ident: e_1_2_6_1_16_1 doi: 10.1038/onc.2011.408 – ident: e_1_2_6_1_22_1 doi: 10.1158/0008-5472.CAN-03-2970 – ident: e_1_2_6_1_54_1 doi: 10.1038/ng1902 – ident: e_1_2_6_1_14_1 doi: 10.1186/s12885-015-1934-1 – ident: e_1_2_6_1_43_1 doi: 10.1038/87876 – volume: 133 start-page: 644 year: 1971 ident: e_1_2_6_1_38_1 article-title: Carcinoma of the breast and ovary in three families publication-title: Surgery, Gynecology and Obstetrics – ident: e_1_2_6_1_62_1 doi: 10.1126/science.8091231 – ident: e_1_2_6_1_9_1 doi: 10.1073/pnas.1706392114 – ident: e_1_2_6_1_46_1 doi: 10.1073/pnas.85.9.3044 – ident: e_1_2_6_1_53_1 doi: 10.1038/ng1096-185 – ident: e_1_2_6_1_39_1 doi: 10.1146/annurev.ge.28.120194.002303 – ident: e_1_2_6_1_24_1 doi: 10.1097/PAS.0b013e31826cabbd – volume: 56 start-page: 3663 issue: 16 year: 1996 ident: e_1_2_6_1_30_1 article-title: High prevalence of the 999del5 mutation in icelandic breast and ovarian cancer patients publication-title: Cancer Research – ident: e_1_2_6_1_44_1 doi: 10.7326/0003-4819-143-5-200509060-00012 – ident: e_1_2_6_1_18_1 doi: 10.1002/ijc.29210 – ident: e_1_2_6_1_59_1 doi: 10.1200/JCO.2008.20.5179 – ident: e_1_2_6_1_60_1 doi: 10.1007/s11033-011-0958-0 – ident: e_1_2_6_1_19_1 doi: 10.1038/onc.2016.502 – ident: e_1_2_6_1_17_1 doi: 10.1038/nature03445 – ident: e_1_2_6_1_7_1 doi: 10.1371/journal.pgen.1002101 – ident: e_1_2_6_1_61_1 doi: 10.1515/BC.2002.030 – ident: e_1_2_6_1_26_1 doi: 10.1136/jcp.2005.032151 – ident: e_1_2_6_1_48_1 doi: 10.1093/carcin/bgq069 – ident: e_1_2_6_1_50_1 doi: 10.1038/82533 – ident: e_1_2_6_1_6_1 doi: 10.1158/0008-5472.CAN-08-1569 – ident: e_1_2_6_1_55_1 doi: 10.1111/cge.12037 – ident: e_1_2_6_1_3_1 doi: 10.1158/0008-5472.CAN-10-1907 – ident: e_1_2_6_1_28_1 doi: 10.1002/cncr.24200 – ident: e_1_2_6_1_36_1 doi: 10.1200/JCO.2004.05.055 – ident: e_1_2_6_1_23_1 doi: 10.1016/j.dnarep.2015.03.002 – ident: e_1_2_6_1_31_1 doi: 10.1093/jnci/90.7.484 – ident: e_1_2_6_1_37_1 doi: 10.1002/humu.10154 – volume: 95 start-page: 866 issue: 11 year: 2004 ident: e_1_2_6_1_64_1 article-title: Role of BRCA1 and BRCA2 as regulators of DNA repair, transcription, and cell cycle in response to DNA damage publication-title: Cancer Prevention Research – ident: e_1_2_6_1_2_1 doi: 10.1086/375033 – ident: e_1_2_6_1_52_1 doi: 10.1038/ng0197-14 – ident: e_1_2_6_1_20_1 doi: 10.1086/301903 – volume: 24 start-page: 410 issue: 5 year: 2010 ident: e_1_2_6_1_42_1 article-title: HER2‐positive breast cancer: Beyond trastuzumab publication-title: Oncology – ident: e_1_2_6_1_12_1 doi: 10.3892/ol.2011.390 – ident: e_1_2_6_1_56_1 doi: 10.1056/NEJM198705213162101 – ident: e_1_2_6_1_29_1 doi: 10.1007/s10552-007-0118-y – ident: e_1_2_6_1_40_1 doi: 10.1002/humu.20169 – ident: e_1_2_6_1_58_1 doi: 10.1016/j.ejmg.2017.07.016 – ident: e_1_2_6_1_41_1 doi: 10.1097/01.pas.0000213428.61374.06 – ident: e_1_2_6_1_49_1 doi: 10.1016/S0065-2660(08)00601-9 – volume: 18 start-page: 107S year: 2000 ident: e_1_2_6_1_51_1 article-title: Immunophenotypic and pathologic differences between BRCA1 and BRCA2 hereditary breast cancers publication-title: Journal of Clinical Oncology – ident: e_1_2_6_1_45_1 doi: 10.1007/s10689-012-9581-z – ident: e_1_2_6_1_57_1 doi: 10.1023/B:JOMG.0000048770.90334.3b – ident: e_1_2_6_1_4_1 doi: 10.1038/sj.bjc.6600008 – ident: e_1_2_6_1_21_1 doi: 10.1056/NEJMra0802968 – ident: e_1_2_6_1_34_1 doi: 10.1056/NEJMoa031759 |
SSID | ssj0009933 |
Score | 2.588477 |
SecondaryResourceType | review_article |
Snippet | The most important cause of developing hereditary breast cancer is germline mutations occurring in breast cancer (BCs) susceptibility genes, for example,... The most important cause of developing hereditary breast cancer is germline mutations occurring in breast cancer (BCs) susceptibility genes, for example, BRCA1... |
SourceID | proquest pubmed crossref wiley |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 5741 |
SubjectTerms | Animals Biomarkers, Tumor - genetics BRCA BRCA1 protein BRCA1 Protein - genetics BRCA2 protein BRCA2 Protein - genetics Breast cancer Breast Neoplasms - genetics Cancer Deoxyribonucleic acid DNA DNA repair Environmental factors Female Genes Genetic Predisposition to Disease Genetic transformation Genetics Genomic instability germline mutations Health risk assessment Health risks hereditary genes Heredity Heterozygosity Homology Humans Loss of Heterozygosity Mutation Ovarian cancer p53 Protein Patients Pedigree Penetrance PTEN protein Risk Assessment Risk Factors Stability |
Title | Hereditary breast cancer; Genetic penetrance and current status with BRCA |
URI | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fjcp.27464 https://www.ncbi.nlm.nih.gov/pubmed/30552672 https://www.proquest.com/docview/2169268707 https://www.proquest.com/docview/2157666836 |
Volume | 234 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3dS9xAEB9EKPTFWq321JZtKaUvOZPsZ_DpeihXoaVIBR-EkP0ItGo8vNyD_vXu7CYRWwulTwlkkt3szuz-Znf2NwAfTG2dzao00cK5hFWcJoWqioRRY3hua-Eknkb--k3MTtnxGT9bgYP-LEzkhxgW3NAywniNBl7pxf4DaegvMx97l0ogFyjGaiEgOnmgjiq6NPIhBIGzrGcVSvP94c3Hc9EfAPMxXg0TztELOO-rGuNMLsbLVo_N3W8sjv_5L-uw1gFRMoma8xJWXLMBm5PGO-FXt-QjCaGhYc19A57FjJW3m_Blhrk9f7a-KKIxnr0lBvXm5oAggbX_FpnjFdN1OFI1lphIAEXw5NJyQXDdl3w-mU5ewenR4Y_pLOmyMSSGcsqSjCtbW5661FoPI6QV0vtvvNbUUSkpk0wbjz-oqKjxQsowJTJbUyor5epM0y1Yba4b9xpIyo3XB869a6OZUUY5Kqz3pBSXrhYqH8Gnvl9K01GVY8aMyzKSLOelb7AyNNgI3g-i88jP8ZTQXt-5ZWeiizLPRJELP1zJEbwbHnvjwh2TqnHXS5Tx7pgQiooRbEelGEpBqrRcSKxs6Nq_F18eT7-Hm51_F92F5x6aFTG0cg9W25ule-PhT6vfBj2_B4oN_mc |
linkProvider | Wiley-Blackwell |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3dT9RAEJ8gxuiLCqicgCzGGF96tN3PRl6Oi-T4jCGQ8EKadnebqFgu0HvAv56d3bYElcT41Caddre7M9v5TWd_A_BBV8aapIijUlgbsYLTKFNFFjGqNU9NJazE3ciHR2JyyvbO-NkcbHV7YQI_RB9wQ8vw6zUaOAakN-9YQ7_r6dBhKsEewWOs6O0B1fEdeVTWFpL3SQicJR2vUJxu9rfe_xr94WLe91j9J2fnBZx3nQ2ZJj-Gs6Yc6l-_8Tj-79u8hOetL0pGQXkWYM7Wi7A0qh0O_3lDPhKfHerD7ovwJBStvFmC3QmW9_zWuLZIiSntDdGoOlefCXJYu2eRKR6xYoclRW2IDhxQBDcvza4Jhn7J9vF49ApOd76cjCdRW5Ah0pRTFiVcmcrw2MbGOE9CGiEdhONVSS2VkjLJSu1cECoKqp2Q0kyJxFSUykLZKinpa5ivL2u7DCTm2qkE5w7dlEwrrSwVxoEpxaWthEoH8KmbmFy3bOVYNOMiDzzLae4GLPcDNoD3veg0UHT8TWi1m928tdLrPE1Elgq3YskBbPSXnX3hT5OitpczlHGITAhFxQDeBK3oW0G2tFRI7Kyf24ebz_fGX_3J238XXYenk5PDg_xg92h_BZ45Ty0LmZarMN9czeya84aa8p1X-ltwtgKR |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LT9wwEB5RKioutEAf29LWVFXVS5YkfkactktXC7QIoSJxQIoS25GAElaQPdBf37GdBNGHVPWUSJnEjj1jf2OPvwF4rytjTVLEUSmsjVjBaZSpIosY1ZqnphJWutPIXw_E9JjtnfCTBdjuzsIEfoh-wc1Zhh-vnYHPTLV1Rxp6rmdDdKkEewAPmYiVU-mdozvuqKzNI-9jEDhLOlqhON3qX70_Gf2GMO8DVj_jTB7DaVfXEGhyMZw35VD_-IXG8T9_5gmstEiUjILqrMKCrddgfVSjF355Sz4QHxvqF93XYCmkrLxdh92pS-551mBRpHQB7Q3RTnGut4ljsMZvkZm7unwdlhS1ITowQBF3dGl-Q9zCL_l0NB49hePJ52_jadSmY4g05ZRFCVemMjy2sTGII6QREh04XpXUUikpk6zUCECoKKhGIaWZEompKJWFslVS0mewWF_V9gWQmGtUCM7RtymZVlpZKgy6UopLWwmVDuBj1y-5brnKXcqM73lgWU5zbLDcN9gA3vWis0DQ8Sehja5z89ZGb_I0EVkqcLySA9jsH6N1uS2TorZXcyeD_pgQiooBPA9K0ZfiuNJSIV1lfdf-vfh8b3zob17-u-hbeHS4M8m_7B7sv4JlhGlZCLPcgMXmem5fIxRqyjde5X8Cf6YBSQ |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Hereditary+breast+cancer%3B+Genetic+penetrance+and+current+status+with+BRCA&rft.jtitle=Journal+of+cellular+physiology&rft.au=Mahdavi%2C+Morteza&rft.au=Nassiri%2C+Mohammadreza&rft.au=Kooshyar%2C+Mohammad+Mahdi&rft.au=Vakili-Azghandi%2C+Masoume&rft.date=2019-05-01&rft.eissn=1097-4652&rft.volume=234&rft.issue=5&rft.spage=5741&rft_id=info:doi/10.1002%2Fjcp.27464&rft_id=info%3Apmid%2F30552672&rft.externalDocID=30552672 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0021-9541&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0021-9541&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0021-9541&client=summon |